Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Piperaquine Tetraphosphate→

Piperaquine Tetraphosphate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
911061-10-4
Molecular formula
C29H44Cl2N6O16P4
Molecular weight
927.5 g/mol
Drug class
Bisquinoline antimalarialblood-schizonticidal agent
Mechanism of action
A bisquinoline antimalarial that interferes with haem detoxification in Plasmodium parasites, leading to accumulation of toxic haem species and parasite death. It is used clinically in combination with dihydroartemisinin; phosphate is a salt component, not a distinct active target.
Indications / reported uses
  • Treatment of uncomplicated Plasmodium falciparum malaria as part of the fixed-dose dihydroartemisinin–piperaquine combination, in accordance with current national malaria guidelines and resistance patterns

Sources: WHO prequalification — Eurartesim product information · EMA EPAR — Eurartesim · WHO Guidelines for malaria

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Piperaquine Tetraphosphate Environmental Risk Assessment (ERA) (the Piperaquine Tetraphosphate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.